Passage Bio, Inc. (PASG) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.95
+5% vs avg
5yr avg: 0.90
30Y Low0.4·High3.8
ROE
↓
-113.8%
↑-55% vs avg
5yr avg: -73.2%
30Y Low-114%·High-47%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PASG Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Passage Bio, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $18M | $37M | $34M | $55M | $75M | $339M | $1.2B | — | — |
| Enterprise Value | $-4361342 | $15M | $22M | $60M | $68M | $210M | $1.0B | — | — |
| P/E Ratio → | -0.39 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.95 | 2.00 | 0.56 | 0.50 | 0.37 | 1.06 | 3.83 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PASG EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
PASG Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -113.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -113.8% | -113.8% | -75.1% | -65.3% | -52.4% | -59.5% | -46.9% | -56.3% | — |
| ROA | -55.3% | -55.3% | -51.2% | -51.8% | -45.5% | -54.3% | -44.3% | -43.0% | -38.2% |
| ROIC | -141.9% | -141.9% | -64.0% | -48.5% | -54.1% | -77.5% | -91.4% | — | — |
| ROCE | -70.6% | -70.6% | -64.8% | -55.7% | -50.3% | -58.7% | -46.9% | -35.7% | -40.6% |
PASG Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $46M exceeds total debt of $24M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.28 | 1.28 | 0.42 | 0.24 | 0.13 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.19 | -0.20 | 0.04 | -0.04 | -0.40 | -0.44 | -0.91 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($46M) exceeds total debt ($24M)
PASG Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Passage Bio, Inc.'s current ratio of 2.07x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.22x to 2.07x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.07 | 2.07 | 4.07 | 7.22 | 10.74 | 11.02 | 14.98 | 45.04 | 108.79 |
| Quick Ratio | 2.07 | 2.07 | 4.07 | 7.22 | 10.74 | 11.02 | 14.98 | 45.04 | 108.79 |
| Cash Ratio | 2.01 | 2.01 | 3.96 | 6.99 | 10.33 | 10.70 | 14.40 | 43.16 | 80.98 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
PASG Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Passage Bio, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $3M | $3M | $3M | $3M | $3M | $2M | $1M | $1M |
Peer Comparison
Compare PASG with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PASGYou | $18M | -0.4 | — | — | — | — | -113.8% | -141.9% | — |
 KRYS | $10B | 50.9 | 58.2 | 54.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RCKT | $366M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
 RARE | $3B | -4.7 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRAX | $8B | -20.9 | — | — | — | — | -45.8% | -65.0% | — |
 SGMO | $75M | -0.4 | — | — | 80.8% | -273.1% | -2891.8% | -5405.6% | — |
 ARWR | $12B | -6706.6 | 95.4 | 73.5 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.2% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
PASG — Frequently Asked Questions
Quick answers to the most common questions about buying PASG stock.
What is Passage Bio, Inc.'s P/E ratio?
Passage Bio, Inc.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
What is Passage Bio, Inc.'s ROE?
Passage Bio, Inc.'s return on equity (ROE) is -113.8%. The historical average is -67.0%.
Is PASG stock overvalued?
Based on historical data, Passage Bio, Inc. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.